title: A selective D3 receptor antagonist YQA14 attenuates methamphetamine-induced behavioral sensitization and conditioned place preference in mice.
abstract: OBJECTIVE
  We have reported that a selective dopamine D3 receptor antagonist YQA14 attenuates cocaine reward and relapse to drug-seeking in mice. In the present study, we investigated whether YQA14 could inhibit methamphetamine (METH)-induced locomotor sensitization and conditioned place preference (CPP) in mice.
  
  
  METHODS
  Locomotor activity was monitored in mice treated with METH (1 mg/kg, ip) daily on d 4-13, followed by a challenge with METH (0.5 mg/kg) on d 21. CPP was examined in mice that were administered METH (1 mg/kg) or saline alternately on each other day for 8 days (METH conditioning). YQA14 was injected intraperitoneally 20 min prior to METH or saline.
  
  
  RESULTS
  Both repetitive (daily on d 4-13) and a single injection (on the day of challenge) of YQA14 (6.25, 12.5 and 25 mg/kg) dose-dependently inhibited the acquisition and expression of METH-induced locomotor sensitization. However, repetitive injection of YQA14 (daily during the METH conditioning) did not alter the acquisition of METH-induced CPP, whereas a single injection of YQA14 (prior to CPP test) dose-dependently attenuated the expression of METH-induced CPP. In addition, the repetitive injection of YQA14 dose-dependently facilitated the extinction and decreased the reinstatement of METH-induced CPP.
  
  
  CONCLUSIONS
  Brain D3 receptors are critically involved in the reward and psychomotor-stimulating effects of METH. Thus, YQA14 deserves further study as a potential medication for METH addiction.
authors.affiliation: Department of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.|Department of Anesthesiology, General Hospital of Beijing Military Command, Beijing 100700, China.
authors.forename: Li
authors.initials: L
authors.lastname: Sun
authors.affiliation: Department of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.|State Key Laboratory of Toxicology and Medical Countermeasures, Beijing 100850, China.|Beijing Key Laboratory of Neuropsychopharmacology, Beijing 100850, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Song
authors.affiliation: Department of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.|State Key Laboratory of Toxicology and Medical Countermeasures, Beijing 100850, China.|Beijing Key Laboratory of Neuropsychopharmacology, Beijing 100850, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.|State Key Laboratory of Toxicology and Medical Countermeasures, Beijing 100850, China.|Beijing Key Laboratory of Neuropsychopharmacology, Beijing 100850, China.
authors.forename: Ri-fang
authors.initials: RF
authors.lastname: Yang
authors.affiliation: Department of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.|State Key Laboratory of Toxicology and Medical Countermeasures, Beijing 100850, China.|Beijing Key Laboratory of Neuropsychopharmacology, Beijing 100850, China.
authors.forename: Ning
authors.initials: N
authors.lastname: Wu
authors.affiliation: Department of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.|State Key Laboratory of Toxicology and Medical Countermeasures, Beijing 100850, China.|Beijing Key Laboratory of Neuropsychopharmacology, Beijing 100850, China.
authors.forename: Rui-bin
authors.initials: RB
authors.lastname: Su
authors.affiliation: Department of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.|State Key Laboratory of Toxicology and Medical Countermeasures, Beijing 100850, China.|Beijing Key Laboratory of Neuropsychopharmacology, Beijing 100850, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Li
mesh_terms: D000818:Animals; D016739:Behavior, Addictive / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D001583:Benzoxazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000494:pharmacology*; D008124:Locomotion / Q000187:drug effects; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D050637:Receptors, Dopamine D3 / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D001583:Benzoxazoles; D000697:Central Nervous System Stimulants; D010879:Piperazines; D050637:Receptors, Dopamine D3; C571881:YQA14; D008694:Methamphetamine